Please Note: This trial is no longer enrolling new participants
A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients with Glioblastoma or Non-Small Cell Lung Cancer
| Protocol No. | CTO-BDTX-1535-101 | Scope | National |
|---|---|---|---|
| Principal Investigator | Misty Shields | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase I/II |
